Total Payments
$64,712
2024 Payments
$50,965
Companies
25
Transactions
95
Medicare Patients
25
Medicare Billing
$1,044
Payment Breakdown by Category
Research$52,927 (81.8%)
Other$6,260 (9.7%)
Food & Beverage$3,038 (4.7%)
Travel$2,216 (3.4%)
Gifts$270.00 (0.4%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $52,927 | 17 | 81.8% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $6,260 | 3 | 9.7% |
| Food and Beverage | $3,038 | 57 | 4.7% |
| Travel and Lodging | $2,216 | 17 | 3.4% |
| Gift | $270.00 | 1 | 0.4% |
Payments by Type
Research
$52,927
17 transactions
General
$11,784
78 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Eli Lilly and Company | $50,965 | 2 | $0 (2024) |
| Sunovion Pharmaceuticals Inc. | $9,062 | 33 | $0 (2017) |
| Takeda Pharmaceuticals U.S.A., Inc. | $1,962 | 15 | $0 (2020) |
| SANOFI-AVENTIS U.S. LLC | $502.84 | 5 | $0 (2019) |
| Respiratory Technologies, Inc. | $346.94 | 13 | $0 (2017) |
| Resmed Corp | $270.00 | 1 | $0 (2017) |
| Melinta Therapeutics, Inc. | $179.69 | 2 | $0 (2018) |
| Genentech USA, Inc. | $152.94 | 3 | $0 (2018) |
| Gilead Sciences Inc | $135.44 | 2 | $0 (2017) |
| Pacira Pharmaceuticals Incorporated | $124.99 | 1 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $50,965 | 2 | Eli Lilly and Company ($50,965) |
| 2023 | $144.42 | 2 | Merck Sharp & Dohme LLC ($96.69) |
| 2022 | $103.44 | 1 | AstraZeneca Pharmaceuticals LP ($103.44) |
| 2021 | $119.21 | 1 | GlaxoSmithKline, LLC. ($119.21) |
| 2020 | $2,072 | 16 | Takeda Pharmaceuticals U.S.A., Inc. ($1,962) |
| 2019 | $357.92 | 4 | Pacira Pharmaceuticals Incorporated ($124.99) |
| 2018 | $556.00 | 11 | SANOFI-AVENTIS U.S. LLC ($192.30) |
| 2017 | $10,394 | 58 | Sunovion Pharmaceuticals Inc. ($9,062) |
All Payment Transactions
95 individual payment records from CMS Open Payments — Page 1 of 4
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 09/17/2024 | Eli Lilly and Company | — | — | Cash or cash equivalent | $49,414.00 | Research |
| Study: A STUDY OF RETATRUTIDE (LY3437943) IN PARTICIPANTS WITH TYPE 2 DIABETES MELLITUS WHO HAVE OBESITY OR OVERWEIGHT (TRIUMPH-2) | ||||||
| 05/30/2024 | Eli Lilly and Company | — | — | In-kind items and services | $1,551.08 | Research |
| Study: A STUDY OF RETATRUTIDE (LY3437943) IN PARTICIPANTS WITH TYPE 2 DIABETES MELLITUS WHO HAVE OBESITY OR OVERWEIGHT (TRIUMPH-2) | ||||||
| 11/15/2023 | Insmed, Inc. | Arikayce (Drug) | Food and Beverage | In-kind items and services | $47.73 | General |
| Category: Respiratory | ||||||
| 01/12/2023 | Merck Sharp & Dohme LLC | VERQUVO (Drug), VERQUVO | Food and Beverage | In-kind items and services | $96.69 | General |
| Category: CARDIOVASCULAR | ||||||
| 10/27/2022 | AstraZeneca Pharmaceuticals LP | TEZSPIRE (Biological) | Food and Beverage | In-kind items and services | $103.44 | General |
| Category: Respiratory | ||||||
| 11/02/2021 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $119.21 | General |
| Category: RESPIRATORY | ||||||
| 01/21/2020 | AcelRx Pharmaceuticals, Inc. | DSUVIA (Drug) | Food and Beverage | Cash or cash equivalent | $109.19 | General |
| Category: PAIN MANAGEMENT | ||||||
| 01/10/2020 | Takeda Pharmaceuticals U.S.A., Inc. | — | — | Cash or cash equivalent | $74.00 | Research |
| Study: A PHASE 1B RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, CROSSOVER STUDY OF 2 SINGLE INTRAVENOUS INFUSION DOSES OF TAK-925 IN SUBJECTS WITH OBSTRUCTIVE SLEEP APNEA WHO ARE EXPERIENCING EXCESSIVE DAYTIME SLEEPINESS DESPITE ADEQUATE USE OF CPAP | ||||||
| 01/10/2020 | Takeda Pharmaceuticals U.S.A., Inc. | — | — | Cash or cash equivalent | $50.00 | Research |
| Study: A PHASE 1B RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, CROSSOVER STUDY OF 2 SINGLE INTRAVENOUS INFUSION DOSES OF TAK-925 IN SUBJECTS WITH OBSTRUCTIVE SLEEP APNEA WHO ARE EXPERIENCING EXCESSIVE DAYTIME SLEEPINESS DESPITE ADEQUATE USE OF CPAP | ||||||
| 01/10/2020 | Takeda Pharmaceuticals U.S.A., Inc. | — | — | Cash or cash equivalent | $50.00 | Research |
| Study: A PHASE 1B RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, CROSSOVER STUDY OF 2 SINGLE INTRAVENOUS INFUSION DOSES OF TAK-925 IN SUBJECTS WITH OBSTRUCTIVE SLEEP APNEA WHO ARE EXPERIENCING EXCESSIVE DAYTIME SLEEPINESS DESPITE ADEQUATE USE OF CPAP | ||||||
| 01/10/2020 | Takeda Pharmaceuticals U.S.A., Inc. | — | — | Cash or cash equivalent | $25.00 | Research |
| Study: A PHASE 1B RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, CROSSOVER STUDY OF 2 SINGLE INTRAVENOUS INFUSION DOSES OF TAK-925 IN SUBJECTS WITH OBSTRUCTIVE SLEEP APNEA WHO ARE EXPERIENCING EXCESSIVE DAYTIME SLEEPINESS DESPITE ADEQUATE USE OF CPAP | ||||||
| 01/09/2020 | Takeda Pharmaceuticals U.S.A., Inc. | — | — | Cash or cash equivalent | $125.00 | Research |
| Study: A PHASE 1B RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, CROSSOVER STUDY OF 2 SINGLE INTRAVENOUS INFUSION DOSES OF TAK-925 IN SUBJECTS WITH OBSTRUCTIVE SLEEP APNEA WHO ARE EXPERIENCING EXCESSIVE DAYTIME SLEEPINESS DESPITE ADEQUATE USE OF CPAP | ||||||
| 01/09/2020 | Takeda Pharmaceuticals U.S.A., Inc. | — | — | Cash or cash equivalent | $109.45 | Research |
| Study: A PHASE 1B RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, CROSSOVER STUDY OF 2 SINGLE INTRAVENOUS INFUSION DOSES OF TAK-925 IN SUBJECTS WITH OBSTRUCTIVE SLEEP APNEA WHO ARE EXPERIENCING EXCESSIVE DAYTIME SLEEPINESS DESPITE ADEQUATE USE OF CPAP | ||||||
| 01/09/2020 | Takeda Pharmaceuticals U.S.A., Inc. | — | — | Cash or cash equivalent | $50.00 | Research |
| Study: A PHASE 1B RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, CROSSOVER STUDY OF 2 SINGLE INTRAVENOUS INFUSION DOSES OF TAK-925 IN SUBJECTS WITH OBSTRUCTIVE SLEEP APNEA WHO ARE EXPERIENCING EXCESSIVE DAYTIME SLEEPINESS DESPITE ADEQUATE USE OF CPAP | ||||||
| 01/09/2020 | Takeda Pharmaceuticals U.S.A., Inc. | — | — | Cash or cash equivalent | $50.00 | Research |
| Study: A PHASE 1B RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, CROSSOVER STUDY OF 2 SINGLE INTRAVENOUS INFUSION DOSES OF TAK-925 IN SUBJECTS WITH OBSTRUCTIVE SLEEP APNEA WHO ARE EXPERIENCING EXCESSIVE DAYTIME SLEEPINESS DESPITE ADEQUATE USE OF CPAP | ||||||
| 01/09/2020 | Takeda Pharmaceuticals U.S.A., Inc. | — | — | Cash or cash equivalent | $25.00 | Research |
| Study: A PHASE 1B RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, CROSSOVER STUDY OF 2 SINGLE INTRAVENOUS INFUSION DOSES OF TAK-925 IN SUBJECTS WITH OBSTRUCTIVE SLEEP APNEA WHO ARE EXPERIENCING EXCESSIVE DAYTIME SLEEPINESS DESPITE ADEQUATE USE OF CPAP | ||||||
| 01/09/2020 | Takeda Pharmaceuticals U.S.A., Inc. | — | — | Cash or cash equivalent | $25.00 | Research |
| Study: A PHASE 1B RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, CROSSOVER STUDY OF 2 SINGLE INTRAVENOUS INFUSION DOSES OF TAK-925 IN SUBJECTS WITH OBSTRUCTIVE SLEEP APNEA WHO ARE EXPERIENCING EXCESSIVE DAYTIME SLEEPINESS DESPITE ADEQUATE USE OF CPAP | ||||||
| 01/08/2020 | Takeda Pharmaceuticals U.S.A., Inc. | — | — | Cash or cash equivalent | $499.46 | Research |
| Study: A PHASE 1B RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, CROSSOVER STUDY OF 2 SINGLE INTRAVENOUS INFUSION DOSES OF TAK-925 IN SUBJECTS WITH OBSTRUCTIVE SLEEP APNEA WHO ARE EXPERIENCING EXCESSIVE DAYTIME SLEEPINESS DESPITE ADEQUATE USE OF CPAP | ||||||
| 01/08/2020 | Takeda Pharmaceuticals U.S.A., Inc. | — | — | Cash or cash equivalent | $50.48 | Research |
| Study: A PHASE 1B RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, CROSSOVER STUDY OF 2 SINGLE INTRAVENOUS INFUSION DOSES OF TAK-925 IN SUBJECTS WITH OBSTRUCTIVE SLEEP APNEA WHO ARE EXPERIENCING EXCESSIVE DAYTIME SLEEPINESS DESPITE ADEQUATE USE OF CPAP | ||||||
| 01/08/2020 | Takeda Pharmaceuticals U.S.A., Inc. | — | — | Cash or cash equivalent | $16.20 | Research |
| Study: A PHASE 1B RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, CROSSOVER STUDY OF 2 SINGLE INTRAVENOUS INFUSION DOSES OF TAK-925 IN SUBJECTS WITH OBSTRUCTIVE SLEEP APNEA WHO ARE EXPERIENCING EXCESSIVE DAYTIME SLEEPINESS DESPITE ADEQUATE USE OF CPAP | ||||||
| 01/02/2020 | Takeda Pharmaceuticals U.S.A., Inc. | — | — | Cash or cash equivalent | $464.52 | Research |
| Study: A PHASE 1B RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, CROSSOVER STUDY OF 2 SINGLE INTRAVENOUS INFUSION DOSES OF TAK-925 IN SUBJECTS WITH OBSTRUCTIVE SLEEP APNEA WHO ARE EXPERIENCING EXCESSIVE DAYTIME SLEEPINESS DESPITE ADEQUATE USE OF CPAP | ||||||
| 01/02/2020 | Takeda Pharmaceuticals U.S.A., Inc. | — | — | Cash or cash equivalent | $348.28 | Research |
| Study: A PHASE 1B RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, CROSSOVER STUDY OF 2 SINGLE INTRAVENOUS INFUSION DOSES OF TAK-925 IN SUBJECTS WITH OBSTRUCTIVE SLEEP APNEA WHO ARE EXPERIENCING EXCESSIVE DAYTIME SLEEPINESS DESPITE ADEQUATE USE OF CPAP | ||||||
| 11/22/2019 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $118.50 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 10/14/2019 | JAZZ PHARMACEUTICALS INC. | XYREM (Drug) | Food and Beverage | In-kind items and services | $22.19 | General |
| Category: NEUROLOGY | ||||||
| 09/10/2019 | SANOFI-AVENTIS U.S. LLC | DISEASE STATE (Drug) | Food and Beverage | In-kind items and services | $92.24 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A STUDY OF RETATRUTIDE (LY3437943) IN PARTICIPANTS WITH TYPE 2 DIABETES MELLITUS WHO HAVE OBESITY OR OVERWEIGHT (TRIUMPH-2) | Eli Lilly and Company | $50,965 | 2 |
| A PHASE 1B RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, CROSSOVER STUDY OF 2 SINGLE INTRAVENOUS INFUSION DOSES OF TAK-925 IN SUBJECTS WITH OBSTRUCTIVE SLEEP APNEA WHO ARE EXPERIENCING EXCESSIVE DAYTIME SLEEPINESS DESPITE ADEQUATE USE OF CPAP | Takeda Pharmaceuticals U.S.A., Inc. | $1,962 | 15 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2021 | 1 | 13 | 13 | $2,525 | $492.02 |
| 2020 | 1 | 12 | 13 | $2,050 | $551.65 |
Total Patients
25
Total Services
26
Medicare Billing
$1,044
Procedure Codes
2
All Medicare Procedures & Services
2 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| G0399 | Home sleep test (hst) with type iii portable monitor, unattended; minimum of 4 channels: 2 respiratory movement/airflow, 1 ecg/heart rate and 1 oxygen saturation | Office | 2021 | 13 | 13 | $2,525 | $492.02 | 19.5% |
| G0399 | Home sleep test (hst) with type iii portable monitor, unattended; minimum of 4 channels: 2 respiratory movement/airflow, 1 ecg/heart rate and 1 oxygen saturation | Office | 2020 | 12 | 13 | $2,050 | $551.65 | 26.9% |
About Dr. Mitchell Rothstein, MD
Dr. Mitchell Rothstein, MD is a Pulmonary Disease healthcare provider based in Jacksonville, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/19/2006. The National Provider Identifier (NPI) number assigned to this provider is 1174576938.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Mitchell Rothstein, MD has received a total of $64,712 in payments from pharmaceutical and medical device companies, with $50,965 received in 2024. These payments were reported across 95 transactions from 25 companies. The most common payment nature is "" ($52,927).
As a Medicare-enrolled provider, Rothstein has provided services to 25 Medicare beneficiaries, totaling 26 services with total Medicare billing of $1,044. Data is available for 2 years (2020–2021), covering 2 distinct procedure/service records.
Ad
Practice Information
- Specialty Pulmonary Disease
- Location Jacksonville, FL
- Active Since 05/19/2006
- Last Updated 01/23/2012
- Taxonomy Code 207RP1001X
- Entity Type Individual
- NPI Number 1174576938
Products in Payments
- UTIBRON (Drug) $9,035
- PRALUENT (Drug) $313.76
- AirCurve (Device) $270.00
- Esbriet (Biological) $132.98
- EXPAREL (Drug) $124.99
- Letairis (Drug) $121.81
- TRELEGY ELLIPTA (Drug) $119.21
- DUPIXENT (Biological) $118.50
- DSUVIA (Drug) $109.19
- Baxdela (Drug) $106.38
- TEZSPIRE (Biological) $103.44
- Bravo (Device) $97.78
- NO PRODUCT DISCUSSED (Drug) $96.84
- VERQUVO (Drug) $96.69
- DISEASE STATE (Drug) $92.24
- Adempas (Drug) $91.95
- Vascepa (Drug) $81.21
- Vabomere (Drug) $73.31
- Respiratoriy Care Undiv (Device) $49.19
- Arikayce (Drug) $47.73
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Pulmonary Disease Doctors in Jacksonville
Dr. Abubakr Bajwa, M.d, M.D
Pulmonary Disease — Payments: $586,209
Pulmonary Disease $586,209
Jorge Mallea, Md, MD
Pulmonary Disease — Payments: $206,363
Pulmonary Disease $206,363
Charles Burger, Md, MD
Pulmonary Disease — Payments: $141,922
Pulmonary Disease $141,922
Dr. Sebastian Fernandez-Bussy, M.d, M.D
Pulmonary Disease — Payments: $125,148
Pulmonary Disease $125,148
Dr. Daniel Wyzan, Md, MD
Pulmonary Disease — Payments: $113,878
Pulmonary Disease $113,878
Peter Nassar, Md, MD
Pulmonary Disease — Payments: $80,367
Pulmonary Disease $80,367